[Federal Register Volume 61, Number 142 (Tuesday, July 23, 1996)]
[Notices]
[Pages 38215-38216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18680]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE
Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1992--Inter Company Collaboration for Aids Drug 
Development

    Notice is hereby given that, on June 26, 1996, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Inter Company Collaboration for 
Aids Drug Development (The Collaboration) filed

[[Page 38216]]

written notifications simultaneously with the Attorney General and the 
Federal Trade Commission. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. The 
following companies (including their affiliates and subsidiaries) are 
parties to the Collaboration: AB Astra, Sodertalje, SWEDEN; Agouron 
Pharmaceuticals, Inc., La Jolla, CA; AJI PHARMA USA, Inc., Teaneck, NJ; 
Bayer Aktiengesellschaft, Leverkusen, GERMANY; Boehringer Ingelheim 
Pharmaceuticals, Inc., Ridgefield, CT; Bristol-Myers Squibb Company, 
New York, NY; Bristol-Myers, Squibb Holdings, Limited, Ickenham, 
Uxbridge, ENGLAND; Bristol-Myers, Squibb, Brussels, BELGIUM; Bristol-
Myers, Brussels, BELGIUM; Bristol-Myers Squibb Canada, Inc., North 
York, Ontario, CANADA; Bristol-Myers Squibb Pharmaceuticals, Limited, 
Middlesex, ENGLAND; Bristol-Myers Squibb S.A., Paris, FRANCE; Bristol-
Myers Squibb G.m.b.H., Munich, GERMANY; Bristol-Myers Squibb S.p.A., 
Rome, ITALY; E.R. Squibb & Sons, Inc., Princeton, NJ; E.R. Squibb & 
Sons Limited, Middlesex, NJ; Mead Johnson & Company, Evansville, IN; 
Squibb Corporation, Princeton, NJ; Ciba-Geigy Limited, Basel, 
SWITZERLAND; The DuPont Merck Pharmaceutical Company, Wilmington, DE; 
Gilead Sciences, Inc., Foster City, CA; Glaxo Wellcome Inc., Research 
Triangle Park, NC; Glaxo Wellcome plc, London, ENGLAND; The Wellcome 
Foundation Ltd., London, ENGLAND; Glaxo Wellcome Inc., Mississauga, 
Ontario, CANADA, Hoechst Ag, Frankfurt am Main, GERMANY; Hoechst Marion 
Roussel Inc., Kansas City, MO; Hoffman-La Roche Inc., Nutley, NJ; 
F.Hoffman-LaRoche Ltd., Basel, SWITZERLAND, Merck & Co., Inc., 
Whitehouse Station, NJ; Pfizer Inc., New York, NY; Pharmacia & Upjohn 
Company, Kalamazoo, MI; Sigma-Tau S.p.A., Pomezia (Rome), ITALY; 
SmithKline Beecham plc, Brentford, Middlesex, ENGLAND and Triangle 
Pharmaceuticals, Inc., Durham, NC.
    The parties to the Collaboration will exchange scientific research 
and development data on HIV antiviral drugs and HIV antiviral compounds 
for comparative and/or concomitant AIDS research and development and to 
develop standardized preclinical testing procedures, essays, and other 
standards and tests for HIV antiviral compounds. The parties will 
coordinate a number of clinical trials of different combinations of 
multiple antiviral drugs recommended by the Collaboration's Clinical 
Trial Subcommittee. The trials will be conducted by clinical research 
organizations selected by the Collaboration, pursuant to a protocol(s) 
approved by the Collaboration that will permit the systematic and rapid 
evaluation of multiple drug combinations. Membership in the 
Collaboration remains open, and the Collaboration intends to file 
additional written notifications disclosing all changes in membership.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 96-18680 Filed 7-22-96; 8:45am]
BILLING CODE 4410-01-M